ABIVAX |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.72 EUR | -0.67% |
|
+2.22% | +49.90% |
| 04-11 | Morgan Stanley Adjusts Price Target on Abivax to $16 From $15, Maintains Equalweight Rating | MT |
| 04-08 | Transcript : ABIVAX Société Anonyme, 2023 Earnings Call, Apr 08, 2024 |
Evolution of the average Target Price on Abivax
Price target over the last 5 years
History of analyst recommendation changes
8744e.xEu8EppAtWQqb208H6h6YEJJp_viuGbJEZfweMZqh-A.vT_Zfdwl3RFBCAF3dPgNVzYPxKiS4lHxWaTBQOsJ9dCIBslizSPSNEY6KA~e00ef23f3ef2d92915a0d2fcc750f394
More recommendations
Analysts' Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
14.82
EUR
Average target price
35.74
EUR
Spread / Average Target
+141.16%
High Price Target
65
EUR
Spread / Highest target
+338.60%
Low Price Target
17.7
EUR
Spread / Lowest Target
+19.43%
Consensus detail
Consensus revision (last 18 months)
Analysts covering Abivax
| Morgan Stanley |
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ABVX Stock
- Consensus Abivax
